Investing Investing Investing

Investing in health care

Summary:  Healthcare companies have weathered the recent price turbulence relatively well. In this article we take a look at the investment opportunities within this sector.


The coronavirus has now been around the world for two years and we have arrived at the 'o' of omicron. The uncertainty surrounding this variant, which according to experts is spreading 2 to 3 times faster than the delta version, has put stock markets under pressure recently. Apart from the economic impact and the effect on financial markets, the advance of the new mutation has put the health sector under a magnifying glass more than ever before. 

Pressure on hospitals is increasing and existing vaccine manufacturers such as Pfizer and Moderna are busy adapting to the new variant. Companies such as Sanofi and GSK – who are collaborating on a corona booster – have achieved positive research results with their vaccine candidate, while the listed company Novavax is awaiting final approval of their vaccine by the European Medicines Agency (EMA) among others. These are all hopeful messages in the fight against the virus. 

I have recently received many questions from investors about investment opportunities within the healthcare sector – usually referred to as 'health care' in the investment world. Aside from the corona events and with the global aging population in mind, I would like to help address these questions. 

What is Health care?

In short: all activities aimed at improving the health of people in a country. Health care includes research to increase knowledge of health, but also the application of this knowledge to improve people's health and to prevent or cure diseases – both physical and psychological.

Scientifically, the fields of biology, chemistry, physics and several social sciences (such as medical sociology and psychology) provide input for the development and improvement of health care. Because health care deals with human life, the sector is also regularly the subject of ethical issues in areas such as euthanasia, genetic engineering and privacy.

Steady growth in the number of seniors worldwide

A major study by the United Nations (UN) states that the international organization expects the number of people in their sixties to grow steadily from 1 billion in 2017 to approximately 2.1 billion in 2050. The UN also sees the life expectancy of the world population increasing from about 65 years at present, to more than 72 years by 2050. Of course expectations differ per region, but the trend is that of life expectancy increasing worldwide.

Increase in expected health care expenditure

An important reason for this trend is the worldwide attention to hygiene (washing hands) by UNICEF, among others. Their efforts in the field of clean drinking water and providing better sanitation contribute to the initiated development of an 'aging population'.

However, for this growing group of elderly people, the need for health care increases later in life, which has challenging consequences. For example, the OECD calculated that health care expenditure as a percentage of the Gross Domestic Product (abbreviated GDP, an explanation can be found here) of all OECD countries together, will increase from 8.8% in 2018 to 10.2% in 2030. In addition to this expected increase, overall GDP is likely to increase as well.

Investing worldwide in health care?

The growing need for care and the associated expenditure on drugs and advanced medical applications offers opportunities for investors. You can of course buy European shares of Roche, GlaxoSmithKline or Sanofi, or American companies such as Merck or Pfizer. However, investing in individual stocks is generally riskier than diversified investing through an investment fund such as the SPDR World Healthcare UCITS ETF or the iShares US Medical Devices UCITS ETF. The first scores an above average 4 stars in the Morningstar sustainability ratings, whilst the second is silver-rated by Morningstar, meaning they expect it to outperform category peers.

What are the main risks? Firstly there is currency risk - the funds are quoted in euros, but contain many foreign companies. Secondly, you run market risk - when financial markets are under pressure, health care stocks will experience that pressure too. In the perspective of investing as a football coach, they are midfielders with attacking impulses.

In a nutshell, these funds are of interest to long-term investors who want to bear equity risk and also want to add nuance to their portfolio with companies active in the health care sector with an above-average focus on sustainability. They are also of interest to those who want to diversify from traditional sectors that appear in many portfolios. 

Please remember that investing involves risk, historical performance is not a guarantee of future of returns and your investments may lose value.

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.